GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation

Author: Zhong JIANI ^{1
,

2} ; Chen HANG ; Liu QIMING ; Zhou SHENGHUA ; Liu ZHENGUO ; Xiao YICHAO
Author Information

1. Department of Cardiovascular Medicine,Second Xiangya Hospital,Central South University,Changsha,410011,China
2. Xiangya School of Medicine,Central South University,Changsha,410008,China
Keywords: Atrial fibrillation; Glucagon-like peptide-1 receptor agonists; Metabolism
From: Journal of Pharmaceutical Analysis 2024;14(5):653-665
CountryChina
Language:Chinese
Abstract: Atrial fibrillation(AF)is the most common cardiac arrhythmia.Many medical conditions,including hypertension,diabetes,obesity,sleep apnea,and heart failure(HF),increase the risk for AF.Car-diomyocytes have unique metabolic characteristics to maintain adenosine triphosphate production.Significant changes occur in myocardial metabolism in AF.Glucagon-like peptide-1 receptor agonists(GLP-1 RAs)have been used to control blood glucose fluctuations and weight in the treatment of type 2 diabetes mellitus(T2DM)and obesity.GLP-1 RAs have also been shown to reduce oxidative stress,inflammation,autonomic nervous system modulation,and mitochondrial function.This article reviews the changes in metabolic characteristics in cardiomyocytes in AF.Although the clinical trial outcomes are unsatisfactory,the findings demonstrate that GLP-1 RAs can improve myocardial metabolism in the presence of various risk factors,lowering the incidence of AF.